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The treatment of a man who attempted suicide after experiencing symptoms of anxi-
ety and aggressiveness associated with the use of androgenic-anabolic steroids (AAS)
is described. This report includes 30 days of inpatient treatment and a 6-month
follow-up. Regular use of fluoxetine apparently prevented the onset of anxiety,
depression, aggressiveness, and suicide ideation, even with the concurrent use of
AAS. The urinary concentration of androgens, metabolites of AAS, and fluoxetine
were monitored through analysis of urinary samples by the Brazilian Laboratory of
Doping Control. Our results are congruent with previous findings describing the risk
of suicide prompted by AAS use as well as the efficacy of fluoxetine in the treatment
of mood disorders associated with the use of anabolic steroids.
K E YWORD S
anabolic androgenic steroids, androgens, attempted suicide, mass spectrometry, performance-
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1 | INTRODUCTION
The use of androgenic anabolic steroids (AAS) can increase the risk of
symptoms of anxiety and aggressiveness (Hall et al., 2005; Pagonis
et al., 2006; Piacentino et al., 2015; Pope et al., 2000).1–6 Likewise, sui-
cide has been reported as one the most frequent causes of unnatural
death of anabolic steroid users.7 Although the management of several
AAS-related disorders has been described,8 reports of treatment and
the prevention of psychiatric symptoms concomitant to the detection
of AAS and other drugs are scarce. To the best of our knowledge, a sin-
gle case series9 has reported the successful treatment of AAS-related
withdrawal and depression in humans with fluoxetine. Similar
responses were found in a controlled experiment using a mouse
model.10 We present the case of a 24-year-old male who attempted
suicide following the use of AAS. The individual was also affected by
depressive symptoms during a brief AAS withdrawal. These symptoms
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were successfully treated with fluoxetine. After discharge, the patient
relapsed back into the use of AAS but did not present symptoms of
anxiety, aggressiveness, or suicide ideation, if a regular intake of fluoxe-
tine was maintained. The use of AAS and fluoxetine by the patient was
monitored by analysis of urinary samples to minimize confounding fac-
tors related to the self-reported use of substances, such as memory
and disclosure bias.11,12 Naturalistic observation of AAS use, such as
this study, is additionally challenged by the use of substances of
unknown composition from illicit markets,13 therefore highlighting the
importance of complementing self-reported data with the analysis of
biological samples.14
2 | MATERIALS AND METHODS
The patient's clinical records were reviewed and described by
obtaining prior informed consent from the patient. A summary of
interventions is described in the “Timeline” image presented in
Figure 1.
Toxicological screening on admission was performed by chromato-
graphic immunoassay, using the AllTest Biotech rapid drug detection
test (Hangzhou, China). One vial (30 mL) of urine was collected in the
first 24 h of admission and three aliquots of 2 mL were dripped into the
test device. A visual scale, showing the reaction of drug molecules with
colored antibodies, was used to provide a positive/negative recent use
of the substances being screened. The following substances and
periods of detectable use are informed by the manufacturer: cocaine,
3 days; cannabis, 1 to 13 days; amphetamine, 9 days; methamphet-
amine, 3 to 5 days; benzodiazepines, 3 to 7 days; opioids, 2 to 3 days;
and 3,4-methylenedioxymethamphetamine (MDMA), 2 to 3 days.
During inpatient treatment, urine samples were collected for
6 days. The patient provided four further samples during outpatient
follow-up. Samples were analyzed for concentrations of fluoxetine,
endogenous androgens, and the xenobiotic metabolites of AAS. The
results and reference ranges are shown in Figure 1. Absolute values
were normalized to a 0 to 1 scale so that parameters with distinct
units and dispersions could be visualized in a single graph. The lower
value detected of each androgen and metabolite corresponds to 0 in
the graph, and the higher value corresponds to 1. A complete list of
urinary concentrations of androgens, metabolites and fluoxetine can
be foundat Supporting Information.
The urine sample preparation was based on enzymatic hydrolysis
and liquid–liquid extraction of AAS. Aliquots of 2 mL urine samples
were spiked with 40 μL of internal standard (Table 1).
During the initial testing procedure (screening), the steroid profile
was estimated by single point calibration. Calibration samples, ie, qual-
ity control of endogenous steroids (CQENDO) were prepared by spik-
ing synthetic urine with endogenous steroids standards in their free
F IGURE 1 Timeline and concentrations of androgen steroids and fluoxetine detected in urine samples. The lower value detected of each
androgen and metabolite corresponds to 0 in the graph, and the higher value corresponds to 1. Sp, Sample number, as referred in the timeline;
PIT, psychiatric inpatient treatment. Androgen steroids: (1) androsterone; (2) etiocholanolone; (3) 5α-androstane, 3α-17β, diol; (4) 5β-androstane,
3α-17β, diol; (5) epitestosterone; (6) testosterone. #: Values out of linear range. (a) Nandrolone; (b) Boldenone; (c) 1-testosterone;
(d) Methandienone; (e) Drostanolone. The analysis of urinary concentration of fluoxetine on sp.8 (D128) was not performed due to insufficient
amounts of urine
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form. Nominal final concentrations of the compounds for the
CQENDO samples are presented inTable 2.
The pH was adjusted with 750 μL of 0.8 M phosphate buffer, and
50 μL of β-glucuronidase obtained from Escherichia coli (E. coli) was
added. It was incubated at 50C for 1 hour, and then 500 μL of aque-
ous buffer solution containing K2CO3/KHCO3 20% (w/w) and 4 mL of
methyl tert-butyl ether (TBME) was added. The mixture was stirred
for 5 min and centrifuged at 3000 rpm for 5 min. After phase separa-
tion, the organic phase was evaporated to dryness under nitrogen and
dried in a vacuum oven for 30 min at room temperature. Finally, the
residue was derivatized with 100 μL of N-methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA)–NH4I–2-mercaptoethanol (1000:2:6,
v/w/v) 60C for 20 minutes. Aliquots of 2 μL were injected in splitless
mode into the triple quadrupole system (GC-QqQ) operated in multi-
ple reaction monitoring mode. The analysis was performed using a gas
chromatograph (GC) Trace 1310 (Thermo Scientific) and interfaced
with a mass spectrometer TSQ 8000 (Thermo Scientific), column
100% methylpolysiloxane phase (17 m × 0.20 mm × 0.11 μm).
List of the reagents: methanol (pesticide grade), ethyl acetate
(GC grade), acetone (GC grade), and tert butyl methyl ether
(GC grade) were purchased from Tedia (Fairfield, OH, USA). N-
Methyl-N-(trimethylsilyl)-trifluoroacetamide, 2-mercaptoethanol, and
ammonium iodide were purchased from Sigma Aldrich (St Louis, MO,
USA). Sodium dihydrogen phosphate monohydrate, di-sodium hydro-
gen phosphate, potassium carbonate, and potassium hydrogen car-
bonate were purchased from Merck KGaA (Darmstadt, Germany).
β-Glucuronidase from E. coli was purchased from Roche Diagnostics
GmbH (Mannheim, Germany). Compressed helium (99.999% purity)
and argonium (99.999% purity) gases were purchased from White
Martins (S~ao Paulo, Brazil). All reference materials were purchased
from the National Measurement Institute (Australia).
The GC electron impact source mass spectrometry (GC-EI-
MS/MS) conditions were: oven temperature program 140 to 230C at
40C/min, 230 to 280C at 3C/min, 280 to 300C and held at 300C
for 3 min. The transfer line was set to 300C and the ion source was
set to 320C. Electron ionization was performed using electron energy
of 70 eV.
The collision energies were optimized according to the software
Auto SRM. The dwell time was set to reach ten points across the peak
for the narrowest peak.
For liquid chromatography (LC), high-resolution mass spectrome-
try (LC-HRMS) conditions, and fluoxetine evaluation the LC separa-
tions were performed on Dionex UltiMate 3000 UHPLC system
(ThermoScientific, using a Syncronis C 18 column (50 × 2.1 mm ×
1.7 μm) maintained at 40C. The mobile phase A (water, 0.1% formic
acid and 5 mM ammonium formate) and mobile phase B (methanol
and 0.1% formic acid) were employed in the following gradient of B
mobile phase: 0 min, 5%; 0.3 min, 5%, 0.5 min, 10%; 1 min 25%;
6 min, 90%; 8 min, 100%; 9 min, 100%; 9.1 min, 5%; 11 min, 5%. The
flow rate was 400 μL/min and the injection volume was 10 μL. For
high resolution mass spectrometry analysis a QExactiveTM Plus
Orbitrap mass spectrometer (MS) (ThermoFisher Scientific, Bremen,
Germany) was used in positive mode ionization. The mass detection
range was m/z 100–900 in data dependent acquisition mode for MS2
fragmentation experiments. The automatic gain control (AGC) target
was set to 1e6 and maximum ion time (IT) was set to 100 ms. The
sheath gas flow rate and the auxiliary gas flow rate were set to 60 and
20 respectively, the spray voltage was 3.90 kV, the capillary tempera-
ture was 380C, the S-lens radio frequency (RF) level 80, the auxiliary
gas heater temperature was 380 C.
Fluoxetine could be detected in tR = 6.15 min with the exact mass
equal to m/z 310.14120. As internal standard 7-propilteofiline was
used. It is detected at tR = 3.75 min and the monitored transition is
m/z 372 ! m/z 210. This internal standard in 50 ng/mL was used to
infer the concentration of fluoxetine in patient urine samples.
The data were evaluated using Thermo Fisher Scientific
TraceFinderTM 3.2.512.0 software (Thermo Fisher Scientific,
Waltham, MA, USA).
This study is registered at the Brazilian Committee for Ethics in
Research under CAAE: 83109618.6.0000.5263.
3 | CASE DESCRIPTION
The patient identified as Mr Y was a 24-year-old man with a history
of AAS use over the previous 6 years. According to the patient's
TABLE 1 Internal standard composition [Colour table can be
viewed at wileyonlinelibrary.com]







TABLE 2 CQENDO composition [Colour table can be viewed at
wileyonlinelibrary.com]
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family members, he had a normal neuropsychological development
and no record of alcohol abuse or consumption of illegal drugs. There
was no history of relevant clinical disorders, surgeries, significant
traumas, allergies, or diagnosed psychiatric disorders. As reported by
his parents, Mr Y's behavior suddenly changed when he was 19 years
old – the time when he started using AAS, as confirmed by the
patient. From that moment on, Mr Y began to display a more aggres-
sive, short-tempered behavior, every time he started a new routine of
AAS, also known as a “cycle”. Mr Y confirmed that he had used differ-
ent AAS in his life, including counterfeit compounds of unknown com-
position, but had not yet required assistance for any effects
associated with the use of anabolic steroids. According to the patient,
20 days before admission into our medical service (henceforth
referred to as D minus 20 or D-20), he started a 14-day AAS cycle
with a substance known as “durateston”, containing 30 mg of testos-
terone propionate, 30 mg of testosterone fenpropionate, 60 mg of
testosterone isocaproate, and 100 mg of testosterone decanoate.
Mr Y experienced episodes of mood swings with severe anxiety
and aggressiveness on D-3, including threatening to kill his partner
due to uncontrollable feelings of jealousy. On D-2, the patient
ingested 20 mg of clonazepam and attempted suicide by hanging him-
self by the neck with a leather belt. Mr Y was found by his parents in
the balcony of his apartment and taken to the emergency department
(ED). There, he recovered consciousness and reacted aggressively to
medical interventions until he was medicated with intramuscular
(IM) injections of midazolam, haloperidol decanoate, promethazine,
chlorpromazine, phenobarbital, and diazepam. Mr Y stayed at the ED
for approximately 24 hours, and was transferred to the psychiatric
facility where this study was conducted on D0 (day zero) for inpatient
treatment. (See the Timeline in Figure 1 for details of pharmacological
treatment and the use of substances informed by the patient).
On admission, a urine toxicological analysis was performed for
screening of recent use of drugs, as described in the Methods section.
This test showed solely the recent use of benzodiazepines, a result
compatible with the drugs recently used by the patient. As the urine
toxicological kit did not include screening for anabolic agents, these
substances were tracked by applying the doping control analytical
protocols described previously.
One week after admission, the patient remained in a depressive
mood, reporting not remembering his suicide attempt or aggressive
behavior. Fluoxetine (20 mg/day) was prescribed on D9 of inpatient
treatment. A significant improvement in mood and disposition was
observed on D16. Blood serum analysis on admission and 3 months
after discharge revealed persistent hormone imbalance. Follicle-
stimulating hormone (FSH) remained below 0.3 mlU/mL for both
measures, luteinizing hormone (LH) remained below 0.12 mlU/mL,
estradiol varied from 45.00 pg/dL to 75.81 pg/dL, prolactin ranged
from 43.10 ng/mL to 17.27 ng/mL, and testosterone varied from
1352 ng/mL to 1500 ng/mL. As shown in Figure 1, urinary analysis
revealed a tendency for regularization of androgen concentrations
during inpatient treatment. For the duration of this report, the patient
did not present health complications or symptoms, apart from those
hereby described, that could have interfered in the study.
Mr Y was discharged from inpatient treatment 30 days after
admission, with an alleged resolution to quit the use of AAS. The
patient refused to attend meetings with a psychologist after dis-
charge, but agreed to regular consultations with the first author, Dr
Amaral. Despite continuous treatment and medical advice, the patient
relapsed back into steroid use, as confirmed by urinary analysis. On
the fourth follow-up consultation (D128), the use of AAS had raised
all androgen concentrations above the 95% upper reference limit.15,16
Mr Y informed us that he had voluntarily halted the use of fluoxe-
tine, 14 days before this consultation because he believed the
antidepressant was no longer necessary. However, the patient
reported severe symptoms of anxiety, leading to our decision to ini-
tiate again treatment with fluoxetine, re-introducing the antidepres-
sant in lower doses. After 4 weeks of 10 mg/day of fluoxetine, the
patient reported only a minor improvement in mood, so the dose
was increased to 20 mg/day with complete remission of depressive
symptoms in the following 20 weeks. Despite all advice, Mr Y was
unwilling to suspend the use of AAS, but adhered to the concurrent
intake of fluoxetine. No further symptoms of anxiety, aggression, or
suicide attempts occurred until the completion of this report,
240 days after admission.
4 | DISCUSSION
It is unusual that AAS users seek psychiatric help for steroid-related
symptoms (17,18; Bates et al., 2019).19 This case is not an exception,
since the patient was admitted into treatment by his family after his
suicide attempt. Although the patient has confirmed the long-term
use of AAS, so establishing causality between the use of steroids and
mood disorders, this case is compromised by the lack of a psychiatric
assessment prior to the use of AAS. Nevertheless, the onset of
aggressive symptoms immediately after an AAS cycle and the patient's
emotional fluctuations during AAS cycles allow us to infer an associa-
tion between the use of AAS and behavioral changes that culminated
in a suicide attempt. Different metabolites of xenobiotic steroids for
the patient were found in each mass spectrometric analysis, therefore
hampering the identification of the specific AAS used during the
period of the study.
When the patient was admitted for psychiatric treatment, bio-
chemical analysis revealed a hormone imbalance compatible with the
chronic use of exogenous testosterone, such as the suppression of
gonadotropins.20 Drugs administered prior to Mr Y's admission,
namely the long-lasting haloperidol decanoate, are confounding fac-
tors for the initial response to medication. Notwithstanding, the
response to fluoxetine was observed for more than 3 months after
the use of haloperidol, as confirmed by chemical monitoring of the
patient's urine samples.
Depressive mood was the most remarkable symptom during the
post-acute phase of AAS intoxication. A short withdrawal was
followed by a relapse into the use of AAS, but no symptoms of anxi-
ety, aggressiveness, insomnia, or depressive mood were observed if a
regular intake of fluoxetine was sustained. Another confounding
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factor for the recurrence of symptoms was the abrupt discontinuation
of fluoxetine, which can be associated with irritability and depressive
symptoms.21 Still, the lack of response to 10 mg of fluoxetine during
the AAS cycles on follow-up support the hypothesis of a dose-related
effect of fluoxetine in successfully treating and preventing the onset
of AAS-triggered aggressiveness and anxiety in this patient, as well as
depressive symptoms related to AAS withdrawal. Prior to this study,
Malone and Dimeff9 described the treatment of psychiatric symptoms
of AAS with fluoxetine, in a case series of four patients. Similarly, Mr
Y noted complete remission of depressive symptoms with a daily
intake of a single dose of 20 mg of fluoxetine. Apparently, the antide-
pressant may have also prevented new episodes of anxiety and
aggressiveness during the concurrent use of AAS, but controlled
experiments with the concurrent use of these substances in humans
are necessary to understand their interaction. Studies with animals
exposed to AAS observed an effect of fluoxetine in reducing aggres-
siveness22 and anxiety-like symptoms during AAS withdrawal.10 Simi-
lar effects were reported when using the 5HT1A receptor agonist
8-OH-DPAT.23 To the best of our knowledge, there are no reports of
pharmaceutical interactions between fluoxetine and AAS. Besides, no
association is observed between the treatment with fluoxetine
and testosterone levels.24 Regarding recommendations for treatment,
it is important to highlight that AAS can trigger or aggravate the
symptoms of mania and hypomania.24 Since fluoxetine has the
potential to induce mania in some patients,25 this drug must be
carefully monitored when prescribed to AAS users, namely in
outpatient settings.
Underlying mechanisms of action of AAS on the serotonergic sys-
tem in animals have been described by several authors,22,23,26–28 and
serotonin signaling is apparently involved in the anxiogenic and
depressive effects observed during AAS withdrawal.29 An increased
risk of suicide in AAS users7 seems to be related to the depressive
and aggressive symptoms experienced by those patients.30,31 This
may be related to the effects of testosterone on the serotonergic
pathways related to suicidality.32 AAS also seem to decrease seroto-
nergic activity in the basal forebrain and dorsal striatum. They also
decrease 5HT1A receptors on the anterior hypothalamus and down-
regulate 5HT1B receptors in the globus pallidus and in the CA1 area
of the hippocampus.22 Therefore they affect the regions involved in
the control of aggression. Another hypothesis is that AAS-related anx-
iety, aggressiveness, and depression are related to decreased synthe-
sis of serotonin and increased cerebral levels of neuroactive
kynurenines.33
The limitations of this study include the lack of access to the pre-
cise AAS composition and doses used by Mr Y. The main confounding
factor is the patient's exposure to unknown steroids and drugs. The
variety of AAS metabolites found in the urine samples precludes the
identification of all the androgens used by the patient. Nevertheless,
the analysis of a range of endogenous and xenobiotic AAS, as pre-
scribed in doping control analysis protocols, gives a reasonable picture
of the substances used by the patient for the duration of this study.
Suggested improvements for future studies include a randomized and
double-blinded controlled experiment, the provision of verified doses
of AAS, regular toxicological screening, and longitudinal psychometric
evaluations.
5 | CONCLUSIONS
The onset of anxiety, aggressiveness, and a suicide attempt were
observed following the use of AAS as well as depressive symptoms
on AAS withdrawal, in congruence with previous reports. Fluoxe-
tine was effective in treating AAS post-cycle depression in this
patient, as well as preventing new episodes of aggressiveness or
suicide attempts despite the patient exposure to subsequent doses
of anabolic steroids. Drug interactions between AAS and fluoxetine
must be monitored due to the risk of induction of mania presented
by both substances. Controlled studies are needed to fully under-
stand the mechanisms of fluoxetine effects over AAS-related
psychiatric symptoms.
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